A Phase 2 interventional study of maraviroc and maraviroc in Human Immunodeficiency Virus-1, sponsored by ViiV Healthcare. Completed at 39 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-06-15.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients. Based on the results from this study, a confirmatory phase 3 study may be conducted.
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
maraviroc (Selzentry, Celsentri) 150 mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir (Reyataz) in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir (Prezista)/ritonavir (Norvir)((800/100 mg) QD or lopinavir/ritonavir (Kaletra, Aluvia)(400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir (Prezista)/ritonavir (Norvir) or lopinavir/ritonavir (Kaletra, Aluvia)(, then the subject must be discontinued from the study.
Drug: maraviroc
emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir/ritonavir (800/100 mg) QD or lopinavir/ritonavir (400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir/ritonavir or lopinavir/ritonavir, then the subject must be discontinued from the study.
Drug: maraviroc
maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
Also known as: maraviroc =Celsentri, Selzentry; atazanavir =Reyataz; ritonavir =Norvir; lopinavir/ritonavir=Kaletra, Aluvia; darunavir=Prezista
emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
Also known as: maraviroc=Celsentri, Selzentry; emtricitabine/tenofovir=Truvada; atazanavir =Reyataz; ritonavir =Norvir; lopinavir/ritonavir=Kaletra, Aluvia
Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL)
Time frame: Week 48
HIV-1 RNA Levels at Baseline
Time frame: Baseline
Change From Baseline in HIV-1 RNA Levels of First 15 Participants at Days 4, 7, 10 and 14
Plasma HIV-1 RNA levels were evaluated for first 15 participants enrolled at United States (U.S) sites only.
Time frame: Baseline , Days 4, 7, 10 and 14
Maximum Observed Plasma Concentration (Cmax) of Maraviroc
Time frame: Day 14 (0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose)
Minimum Observed Plasma Concentration (Cmin) of Maraviroc
Time frame: Day 14 (0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose)
Average Observed Plasma Concentration (Cavg) of Maraviroc
Cavg was described as area under the plasma concentration-time profile from time zero to time 24 hours (AUC24) divided by the dosing interval (AUC24/ 24).
Time frame: Day 14 (0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose)
Change From Baseline in Plasma log10 Viral Load at Weeks 16, 24, 48 and 96
Time frame: Baseline, Week 16, Week 24, Week 48, Week 96
Percentage of Participants With Less Than 50 Copies/mL of HIV-1 RNA
Time frame: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, Week 96
Percentage of Participants With Less Than 400 Copies/mL of HIV-1 RNA
Time frame: Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, Week 96
Time to Loss of Virological Response (TLOVR)
TLOVR (virological failure) was defined as the time from first dose of study treatment (Day 1) until the time of virologic failure using the time to loss of virologic response algorithm.
Time frame: Baseline through Week 96
Time-Averaged Difference (TAD) in log10 Viral Load
TAD was calculated as area under the curve of HIV divided by time period minus baseline HIV where HIV was denoted as HIV-1 RNA (log10 copies/mL).
Time frame: Week 16, Week 24, Week 48, Week 96
Change From Baseline in Cluster of Differentiation 4+T Lymphocyte (CD4) Cell Counts at Weeks 16, 24, 48 and 96
Time frame: Baseline, Week 16, Week 24, Week 48, Week 96
Change From Baseline in Cluster of Differentiation 8+T Lymphocyte (CD8) Cell Count at Weeks 16, 24, 48 and 96
Time frame: Baseline, Week 16, Week 24, Week 48, Week 96
Number of Participants With Genotypic Resistance
Genotypic resistance was assessed for all participants at screening and was evaluated for protease inhibitors (PIs), Nucleotide reverse transcriptase inhibitors (NRTIs), and non-NRTIs (NNRTIs) using Monogram GenoSeq and/or PhenoSenseGT assays. This was then repeated for all participants with HIV-1 viral load more than 500 copies/mL either at treatment failure or at early termination, up to Week 96.
Time frame: Week 96 or Time of treatment failure
Number of Participants With Phenotypic Resistance
Phenotypic resistance was assessed for all participants at screening and was evaluated for PIs, NRTIs, and NNRTIs using Monogram GenoSeq and/or PhenoSenseGT assays. This was then repeated for all participants with HIV-1 viral load more than 500 copies/mL either at treatment failure or at early termination, up to Week 96.
Time frame: Week 96 or Time of treatment failure
Number of Participants With HIV-1 RNA Tropism Status Using Trofile Assay
Viral tropism was determined using the trofile assay with enhanced sensitivity for participants with HIV-1 RNA greater than equal to 1000 copies/mL. The enhanced trofile assay had the sensitivity to detect 100 percent of spiked samples when C-X-C chemokine receptor type 4 {CXCR4} \[X4\]-using HIV-1 RNA represented 0.3 percent of the total viral population.
Time frame: Baseline to Week 96 or Time of treatment Failure
| Milestone | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Started | 65 | 64 |
| Treated | 60 | 61 |
| Completed | 50 | 52 |
| Not completed | 15 | 12 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Randomized but not treated | 5 | 3 |
| Withdrew: Other | 1 | 3 |
| Percentage of participants | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL) | 74.60 (63.47 to 85.69) | 83.60 (74.32 to 92.90) |
| copies/mL | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| HIV-1 RNA Levels at Baseline | 84982 ± 127008 | 114827 ± 149638 |
Plasma HIV-1 RNA levels were evaluated for first 15 participants enrolled at United States (U.S) sites only.
| copies/mL | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Change at Day 4 | 1800.00 ± 37351.09 | -46479.40 ± 62259.15 |
| Change at Day 7 | -36947.90 ± 28463.80 | -52137.10 ± 68684.14 |
| Change at Day 10 | -58595.80 ± 66157.66 | -54925.90 ± 70846.93 |
| Change at Day 14 | -47271.60 ± 38234.34 | -55449.90 ± 71207.16 |
| nanogram (ng)/mL | Maraviroc+ Atazanavir / Ritonavir |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Maraviroc | 650 (178 to 1490) |
| ng/mL | Maraviroc+ Atazanavir / Ritonavir |
|---|---|
| Minimum Observed Plasma Concentration (Cmin) of Maraviroc | 37.0 (8.4 to 92.7) |
Cavg was described as area under the plasma concentration-time profile from time zero to time 24 hours (AUC24) divided by the dosing interval (AUC24/ 24).
| ng/mL | Maraviroc+ Atazanavir / Ritonavir |
|---|---|
| Average Observed Plasma Concentration (Cavg) of Maraviroc | 185.10 ± 71.08 |
| log10 copies/ml | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Baseline (n= 59, 61) | 84982 ± 127008 | 114827 ± 149638 |
| Change at Week 16 (n= 54, 58) | -89859.1 ± 131317.35 | -107684.6 ± 149476.47 |
| Change at Week 24 (n= 56, 58) | -87241.2 ± 129638.57 | -110498.1 ± 149836.29 |
| Change at Week 48 (n= 53, 54) | -82343.4 ± 119356.62 | -115582.9 ± 153705.26 |
| Change at Week 96 (n= 49, 51) | -80117.7 ± 121443.50 | -99662.6 ± 116525.87 |
| Percentage of participants | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Week 2 (n= 55, 60) | 0 (0 to 0) | 6.60 (0.35 to 12.77) |
| Week 4 (n= 57, 60) | 8.50 (1.37 to 15.58) | 21.30 (11.03 to 31.59) |
| Week 8 (n= 57, 59) | 47.50 (34.72 to 60.20) | 42.60 (30.21 to 55.03) |
| Week 12 (n= 55, 59) | 61.00 (48.57 to 73.46) | 62.30 (50.13 to 74.46) |
| Week 16 (n= 54, 58) | 72.90 (61.54 to 84.23) | 73.80 (62.73 to 84.81) |
| Week 20 (n= 56, 57) | 71.20 (59.63 to 82.74) | 83.61 (74.32 to 92.90) |
| Week 24 (n= 56, 58) | 81.36 (71.42 to 91.29) | 88.52 (80.53 to 96.52) |
| Week 32 (n= 55, 57) | 79.66 (69.39 to 89.93) | 88.52 (80.53 to 96.52) |
| Week 40 (n= 54, 55) | 81.36 (71.42 to 91.29) | 88.52 (80.53 to 96.52) |
| Week 48 (n= 53, 54) | 74.58 (63.47 to 85.69) | 83.61 (74.32 to 92.90) |
| Week 60 (n= 52, 53) | 67.80 (55.87 to 79.72) | 85.25 (76.35 to 94.15) |
| Week 72 (n= 52, 53) | 74.58 (63.47 to 85.69) | 81.97 (72.32 to 91.62) |
| Week 84 (n= 50, 52) | 76.27 (65.42 to 87.13) | 83.61 (74.32 to 92.90) |
| Week 96 (n= 49, 51) | 67.80 (55.87 to 79.72) | 81.97 (72.32 to 91.62) |
| Percentage of participants | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Week 2 (n= 55, 60) | 27.12 (15.77 to 38.46) | 34.43 (22.50 to 46.35) |
| Week 4 (n= 57, 60) | 50.85 (38.09 to 63.60) | 52.46 (39.93 to 64.99) |
| Week 8 (n= 57, 59) | 79.66 (69.39 to 89.93) | 77.05 (66.50 to 87.60) |
| Week 12 (n= 55, 59) | 89.83 (82.12 to 97.54) | 88.52 (80.53 to 96.52) |
| Week 16 (n= 54, 58) | 88.14 (79.88 to 96.39) | 91.80 (84.92 to 98.69) |
| Week 20 (n= 56, 57) | 89.83 (82.12 to 97.54) | 93.44 (87.23 to 99.65) |
| Week 24 (n= 56, 58) | 91.53 (84.42 to 98.63) | 93.44 (87.23 to 99.65) |
| Week 32 (n= 55, 57) | 89.83 (82.12 to 97.54) | 93.44 (87.23 to 99.65) |
| Week 40 (n= 54, 55) | 91.53 (84.42 to 98.63) | 90.16 (82.69 to 97.64) |
| Week 48 (n= 53, 54) | 89.83 (82.12 to 97.54) | 86.89 (78.41 to 95.36) |
| Week 60 (n= 52, 53) | 86.44 (77.70 to 95.18) | 86.89 (78.41 to 95.36) |
| Week 72 (n= 52, 53) | 86.44 (77.70 to 95.18) | 85.25 (76.35 to 94.15) |
| Week 84 (n= 50, 52) | 81.36 (71.42 to 91.29) | 85.25 (76.35 to 94.15) |
| Week 96 (n= 49, 51) | 77.97 (67.39 to 88.54) | 83.61 (74.32 to 92.90) |
TLOVR (virological failure) was defined as the time from first dose of study treatment (Day 1) until the time of virologic failure using the time to loss of virologic response algorithm.
| Days | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Time to Loss of Virological Response (TLOVR) | 436.2 ± 22.5 | 463.8 ± 16.1 |
TAD was calculated as area under the curve of HIV divided by time period minus baseline HIV where HIV was denoted as HIV-1 RNA (log10 copies/mL).
| log10 copies/mL | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Week 16 | -2.459 ± 0.046 | -2.402 ± 0.045 |
| Week 24 | -2.663 ± 0.048 | -2.626 ± 0.046 |
| Week 48 | -2.897 ± 0.046 | -2.868 ± 0.050 |
| Week 96 | -2.998 ± 0.055 | -3.001 ± 0.053 |
| cells/microliter (cells/mcL) | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Baseline (n= 59, 61) | 357.70 ± 123.53 | 390.00 ± 152.34 |
| Change at Week 16 (n= 54, 58) | 169.60 ± 117.20 | 139.80 ± 102.62 |
| Change at Week 24 (n= 54, 57) | 188.90 ± 125.14 | 173.30 ± 130.55 |
| Change at Week 48 (n= 52, 53) | 215.70 ± 166.59 | 226.60 ± 138.04 |
| Change at Week 96 (n= 50, 51) | 287.50 ± 173.23 | 298.50 ± 160.54 |
| cells/mcL | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Baseline (n= 59, 61) | 931.10 ± 446.26 | 1125.60 ± 735.08 |
| Change at Week 16 (n= 54, 58) | 63.70 ± 290.49 | -153.80 ± 473.96 |
| Change at Week 24 (n= 54, 57) | 6.20 ± 334.89 | -178.00 ± 508.75 |
| Change at Week 48 (n= 52, 53) | -76.80 ± 354.48 | -267.60 ± 574.22 |
| Change at Week 96 (n= 50, 51) | -63.00 ± 355.60 | -231.40 ± 516.99 |
Genotypic resistance was assessed for all participants at screening and was evaluated for protease inhibitors (PIs), Nucleotide reverse transcriptase inhibitors (NRTIs), and non-NRTIs (NNRTIs) using Monogram GenoSeq and/or PhenoSenseGT assays. This was then repeated for all participants with HIV-1 viral load more than 500 copies/mL either at treatment failure or at early termination, up to Week 96.
| Participants | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Number of Participants With Genotypic Resistance | 0 | 0 |
Phenotypic resistance was assessed for all participants at screening and was evaluated for PIs, NRTIs, and NNRTIs using Monogram GenoSeq and/or PhenoSenseGT assays. This was then repeated for all participants with HIV-1 viral load more than 500 copies/mL either at treatment failure or at early termination, up to Week 96.
| Participants | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Number of Participants With Phenotypic Resistance | 0 | 0 |
Viral tropism was determined using the trofile assay with enhanced sensitivity for participants with HIV-1 RNA greater than equal to 1000 copies/mL. The enhanced trofile assay had the sensitivity to detect 100 percent of spiked samples when C-X-C chemokine receptor type 4 {CXCR4} \[X4\]-using HIV-1 RNA represented 0.3 percent of the total viral population.
| Participants | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir |
|---|---|---|
| Baseline | 60 | 61 |
| Week 96 or Time of treatment Failure | 0 | 0 |
Collected over Baseline to follow-up period (28 days after the last dose of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maraviroc+ Atazanavir / Ritonavir | — | 13/60 (21.7%) | 55/60 (91.7%) |
| Atazanavir / Ritonavir + Emtricitabine/ Tenofovir | — | 11/61 (18%) | 58/61 (95.1%) |
| Event | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine/ Tenofovir |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/60 | 0/61 |
| Bronchogenic cystCongenital, familial and genetic disorders | 1/60 | 0/61 |
| Intestinal perforationGastrointestinal disorders | 1/60 | 0/61 |
| Anogenital wartsInfections and infestations | 1/60 | 1/61 |
| CellulitisInfections and infestations | 1/60 | 0/61 |
| Gastroenteritis viralInfections and infestations | 1/60 | 0/61 |
| Tendon ruptureInjury, poisoning and procedural complications | 1/60 | 0/61 |
| CostochondritisMusculoskeletal and connective tissue disorders | 1/60 | 0/61 |
| Cognitive disorderNervous system disorders | 1/60 | 0/61 |
| NephrolithiasisRenal and urinary disorders | 1/60 | 0/61 |
| Event | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine/ Tenofovir |
|---|---|---|
| HyperbilirubinaemiaHepatobiliary disorders | 18/60 | 16/61 |
| NauseaGastrointestinal disorders | 6/60 | 16/61 |
| DiarrhoeaGastrointestinal disorders | 15/60 | 14/61 |
| Ocular icterusEye disorders | 13/60 | 7/61 |
| JaundiceHepatobiliary disorders | 10/60 | 6/61 |
| SinusitisInfections and infestations | 10/60 | 3/61 |
| HeadacheNervous system disorders | 6/60 | 9/61 |
| VomitingGastrointestinal disorders | 8/60 | 6/61 |
| BronchitisInfections and infestations | 8/60 | 5/61 |
| Upper respiratory tract infectionInfections and infestations | 8/60 | 8/61 |
| Age Continuous(Years) | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir | Total |
|---|---|---|---|
| Mean | 38.3 ± 10.2 | 35.3 ± 10.5 | 36.8 ± 10.4 |
| Sex: Female, Male(Participants) | Maraviroc+ Atazanavir / Ritonavir | Atazanavir / Ritonavir + Emtricitabine / Tenofovir | Total |
|---|---|---|---|
| Female | 4 | 9 | 13 |
| Male | 56 | 52 | 108 |
The record gives a start of Mar 2009, a primary completion of Jul 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc